Trial Profile

A Phase 1 Dose-Escalation and Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 17 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs WU-CART-007 (Primary) ; Cyclophosphamide; Fludarabine
Indications Precursor cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors WUGEN

05 Dec 2025 Results presented in the WUGEN Media Release.
05 Dec 2025 According to a WUGEN media release, the company will present Phase 1/2 correlative data and long-term follow-up update for its investigational cell therapy (WU-CART-007) at the American Society of Hematology (ASH) Annual Meeting & Exposition, Dec. 6-9 in Orlando.
25 Sep 2025 Actual primary completion date changed from 1 Jun 2024 to 8 Aug 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com